logo
Why More Patients Are Choosing This Game-Changing Hip Replacement

Why More Patients Are Choosing This Game-Changing Hip Replacement

For over three years, a chemical engineer in his early 50s, working in Malaysia, lived with pain that gradually stole his mobility, independence, and peace of mind. Every step reminded him of what he had lost – long walks, work trips, even simple tasks like tying his shoelaces. His limp in the right leg wasn't just physical; it weighed heavily on his spirit too.
Dr. Narayan Hulse – A leading orthopaedic surgeon specializing in robotic joint replacement
Determined to find a solution, he consulted multiple surgeons in Delhi and Mumbai, but none could offer lasting relief. Doctors told him he had Avascular Necrosis (AVN) – a condition that cuts off blood supply to the hip bone, causing it to weaken and collapse. His problems began after a COVID-19 infection, and though he underwent two surgeries in Mumbai, neither brought relief. As an engineer, he believed in science and precision. He had done his research. He wasn't afraid of surgery – but he was tired of failure.
Then, he came across a therapy he hadn't heard much about before: Robotic Direct Anterior Hip Replacement (DAA).
That decision changed everything.
A Modern Twist to a Classic Surgery
Total hip replacement isn't new. It has helped millions walk again. But what's different about the Robotic Direct Anterior Approach is how it's done – and what it avoids.
Most traditional hip replacements access the joint from the back (posterior) or side (lateral), often cutting through or detaching essential muscles. This could lead to more pain, a longer recovery, and a higher risk of dislocation.
With the DAA technique, the surgeon enters from the front of the hip, sliding between muscles rather than cutting through them. This muscle-sparing approach, combined with robotic guidance, makes the surgery less invasive, highly precise, and allows for faster healing. It is becoming a preferred approach worldwide for these reasons.
Precision Meets Recovery: The Power of Robotic Assistance
Robotic technology does not replace the surgeon – it enhances the surgeon's accuracy. Before surgery, a 3D model of the patient's hip is created. This helps the surgeon decide the exact size, position, and angle of the implant needed.
During the operation, the robot provides real-time feedback, ensuring the implant is placed exactly where it should be. This minimizes errors such as leg length mismatch and poor alignment – common concerns in traditional surgeries.
The Engineers Turnaround
For our 53-year-old patient, the first robotic DAA surgery on his left hip involved an incision of just about 8 cm – less than half the size of traditional cuts. Because no major muscles were cut, he was able to stand and walk with support on the very same day.
Four months later, his second hip was replaced using the same method. His recovery was smooth – no pain, no limping, no complications.
'After living with discomfort for so long, I couldn't believe how quickly I was able to move again,' he said. 'This therapy didn't just fix my hips – it gave me back the rhythm of my life.'
What Makes Robotic DAA Therapy Stand Out
Faster Recovery with Less Pain: Since no major muscles are cut, your body heals faster and with less discomfort.
Smaller Incision, Less Scarring: The 8 cm cut means minimal skin and tissue damage.
Better Accuracy with Robotic Help: The robot helps the surgeon position the new joint perfectly.
Walk Sooner: Most patients can walk with support within hours of surgery.
Balanced Leg Length: Robotic precision ensures both legs are equal in length – avoiding limping.
Lasting Results: Accurate implant positioning improves durability and lowers the chance of needing revision surgery.
Expert Insight
Dr. Narayan Hulse, a leading orthopedic surgeon specializing in robotic joint replacement, explains, 'Robotic DAA therapy combines the best of both worlds – a minimally invasive front-access approach and the unmatched precision of robotic technology. The result is a safer, faster, and more natural recovery for patients. However, surgeons should train themselves properly and hospitals should acquire the required technology and instrumentation to provide this service to needy patients.'
The Takeaway
This isn't just about a new kind of surgery – it's about a new kind of life after surgery. For patients living with AVN, arthritis, or chronic hip pain, Robotic DAA Hip Replacement therapy offers not just hope but a real, science-backed solution.
If walking has become a struggle and pain your new normal, know that you have options. Thanks to advancements like Robotic DAA, those options are better, faster, and more reliable than ever before.
If you or a loved one suffers from chronic hip pain, consult an orthopedic specialist to learn if Robotic DAA Hip Replacement is right for you.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine
Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine

Economic Times

time12 hours ago

  • Economic Times

Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine

In a landmark advancement for oncology and personalized medicine, Russia's Gamaleya National Research Center of Epidemiology and Microbiology—the creators of the Sputnik V COVID-19 vaccine—announced this year that it will begin human clinical trials of the world's first personalized mRNA-based melanoma vaccine within the next few months. Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions. Q. What are melanoma cellsA. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early. Q. What is mRNA, and how is it used in vaccines? A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body. This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer elaborated that the entire vaccine development cycle—from tumor sequencing to vaccine production—can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies. Q. What is a personalized cancer vaccine?A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis. The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers. The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.

Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine
Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine

Time of India

time12 hours ago

  • Time of India

Cancer cure? Russia commences human trials of revolutionary personalized cancer vaccine

In a landmark advancement for oncology and personalized medicine, Russia's Gamaleya National Research Center of Epidemiology and Microbiology—the creators of the Sputnik V COVID-19 vaccine—announced this year that it will begin human clinical trials of the world's first personalized mRNA-based melanoma vaccine within the next few months. Alexander Gintsburg, director of the Gamaleya Center, confirmed that this groundbreaking vaccine, tailored specifically to the genetic profile of individual patients' tumors, will start experimental administration as early as September-October 2025 in collaboration with leading Russian oncology institutions . Explore courses from Top Institutes in Please select course: Select a Course Category Cybersecurity CXO others Public Policy Healthcare Digital Marketing Degree MBA Artificial Intelligence Others PGDM Data Science Data Analytics Product Management MCA Operations Management Leadership Design Thinking Project Management Finance Management healthcare Technology Data Science Skills you'll gain: Duration: 10 Months MIT xPRO CERT-MIT xPRO PGC in Cybersecurity Starts on undefined Get Details Q. What are melanoma cells by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 most beautiful women in the world Undo A. Melanoma cells come from melanocytes, the skin cells that give it color. When these cells grow too much and become cancerous, they cause melanoma, a dangerous kind of skin cancer that can spread fast if not treated early. Q. What is mRNA, and how is it used in vaccines? A. mRNA, or messenger RNA, is a molecule that carries genetic instructions from DNA to the cell's protein-making machinery. It acts like a messenger, conveying the code needed to build specific proteins that perform various functions in the body. In vaccines, mRNA teaches cells to produce a harmless piece of a virus or cancer antigen, triggering the immune system to respond and protect the body. Live Events This novel cancer vaccine is designed to train the immune system to recognize and attack melanoma cells by creating a bespoke mRNA blueprint derived from each patient's unique tumor mutations. The process involves sophisticated artificial intelligence algorithms that analyze the tumor's genetic data to produce a molecular template, which is then synthesized at Gamaleya's production facilities. This tailor-made mRNA encodes proteins that activate a targeted cytotoxic immune response, aiming not only to eradicate primary tumors but also to address metastatic cancer sites. Gintsburg elaborated that the entire vaccine development cycle—from tumor sequencing to vaccine production—can be completed within about one week due to AI-assisted mathematical modeling and neural network computing. This rapid manufacture represents a significant leap compared to typical timelines in personalized cancer therapies. Q. What is a personalized cancer vaccine? A. Personalized cancer vaccine is a tailored immunotherapy designed to train the patient's immune system to recognize and attack their specific cancer cells. It uses information from the patient's tumor genetics to create a unique vaccine that targets tumor-specific mutations, differing from general vaccines. The vaccine model was developed starting in mid-2022 and has already demonstrated promising efficacy in preclinical animal studies, showing the ability to suppress tumor growth and reduce metastasis. The upcoming Phase I clinical trials will take place at two of Russia's foremost oncology centers: the Hertsen Research Institute and the N.N. Blokhin National Medical Research Center of Oncology in Moscow. Importantly, this tailored vaccine is part of a wider Russian initiative to advance cancer treatment across various difficult-to-treat types, including pancreatic, kidney, and non-small-cell lung cancers. The Russian Ministry of Health classifies this vaccine development and approval under a new, specialized regulatory process recognizing its individualized nature, differing fundamentally from traditional drug registration. The state plans to provide this cancer vaccine free of charge to Russian citizens, with an estimated production cost of around 300,000 rubles (approx. USD 2,869) per dose covered by government funding. According to health authorities, about 4 million Russians live with cancer, and approximately 625,000 new cancer cases are diagnosed annually, underlining the urgent need for innovative therapies. The vaccine's success could mark a pivotal moment in Russia's fight against cancer and elevate its personalized medicine program. Unlike the COVID-19 mRNA vaccines designed to target a single viral antigen, this personalized cancer vaccine encodes multiple neoantigens specific to each patient's tumor, offering a multi-targeted immune approach.

The contagion scale: From measles to TB which disease spread fastest?
The contagion scale: From measles to TB which disease spread fastest?

Business Standard

time12 hours ago

  • Business Standard

The contagion scale: From measles to TB which disease spread fastest?

When the Covid pandemic hit, many people turned to the eerily prescient film Contagion (2011) for answers – or at least for catharsis. Suddenly, its hypothetical plot felt all too real. Applauded for its scientific accuracy, the film offered more than suspense – it offered lessons. One scene in particular stands out. Kate Winslet's character delivers a concise lesson on the infectious power of various pathogens – explaining how they can be spread from our hands to the many objects we encounter each day – 'door knobs, water fountains, elevator buttons and each other'. These everyday objects, known as fomites, can become silent vehicles for infection. She also considered how each infection is given a value called R0 (or R-nought) based on how many other people are likely to become infected from another. So, for an R0 of two, each infected patient will spread the disease to two others. Who will collectively then give it to four more. And so a breakout unfolds. The R0 measure indicates how an infection will spread in a population. If it's greater than one (as seen above), the outcome is disease spread. An R0 of one means the level of people being infected will remain stable, and if it's less than one, the disease will often die out with time. Circulating infections spread through a variety of routes and differ widely in how contagious they are. Some are transmitted via droplets or aerosols – such as those released through coughing or sneezing – while others spread through blood, insects (like ticks and mosquitoes), or contaminated food and water. But if we step back to think about how we can protect ourselves from developing an infectious disease, one important lesson is in understanding how they spread. And as we'll see, it's also a lesson in protecting others, not just ourselves. Here is a rundown of some of the most and least infectious diseases on the planet. In first place for most contagious is measles. Measles has made a resurgence globally in recent years, including in high-income countries like the UK and US. While several factors contribute to this trend, the primary cause is a decline in childhood vaccination rates. This drop has been driven by disruptions such as the Covid pandemic and global conflict, as well as the spread of misinformation about vaccine safety. The R0 number for measles is between 12 and 18. If you do the maths, two cycles of transmission from that first infected person could lead to 342 people catching the illness. That's a staggering number from just one patient – but luckily, the protective power of vaccination helps reduce the actual spread by lowering the number of people susceptible to infection. Measles is extraordinarily virulent, spreading through tiny airborne particles released during coughing or sneezing. It doesn't even require direct contact. It's so infectious that an unvaccinated person can catch the virus just by entering a room where an infected person was present two hours earlier. People can also be infectious and spread the virus before they develop symptoms or have any reason to isolate. Other infectious diseases with high R0 values include pertussis, or whooping cough (12 to 17), chickenpox (ten to 12), and Covid, which varies by subtype but generally falls between eight and 12. While many patients recover fully from these conditions, they can still lead to serious complications, including pneumonia, seizures, meningitis, blindness, and, in some cases, death. Low spread, high stakes At the other end of the spectrum, a lower infectivity rate doesn't mean a disease is any less dangerous. Take tuberculosis (TB), for example, which has an R0 ranging from less than one up to four. This range varies depending on local factors like living conditions and the quality of available healthcare. Caused by the bacterium] Mycobacterium tuberculosis, TB is also airborne but spreads more slowly, usually requiring prolonged close contact with someone with the active disease. Outbreaks tend to occur among people who share living spaces – such as families, households, and in shelters or prisons. The real danger with TB lies in how difficult it is to treat. Once established, it requires a combination of four antibiotics taken over a minimum of six months. Standard antibiotics like penicillin are ineffective, and the infection can spread beyond the lungs to other parts of the body, including the brain, bones, liver and joints. What's more, cases of drug-resistant TB are on the rise, where the bacteria no longer respond to one or more of the antibiotics used in treatment. Other diseases with lower infectivity include Ebola – which is highly fatal but spreads through close physical contact with bodily fluids. Its R0 ranges from 1.5 to 2.5. Diseases with the lowest R0 values – below one – include Middle East respiratory syndrome (Mers), bird flu and leprosy. While these infections are less contagious, their severity and potential complications should not be underestimated. The threat posed by any infectious disease depends not only on how it affects the body, but also on how easily it spreads. Preventative measures like immunisation play a vital role – not just in protecting people, but also in limiting transmission to those who cannot receive some vaccinations – such as infants, pregnant women and people with severe allergies or weakened immune systems. These individuals are also more vulnerable to infection in general. This is where herd immunity becomes essential. By achieving widespread immunity within the population, we help protect people who are most susceptible.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store